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Purpose: Osteoarthritis (OA) is the most common joint disease and up
to date there are no therapies to halt disease initiation or progression. It
is becoming more evident that all other joint structures are affected in
OA and that the progressive pathological changes in the joint tissues
perpetuate disease progression. The synovial membrane (SM) functions
as an important site for this complex cell interaction and the molecular
interplay. There is an increasing body of evidence that synovitis in OA
may not just result from, but also play an active role in disease onset and
progression. This could lead to a disturbed immune regulation in OA
joints with the predominance of inﬂammatory cells on one hand and a
defective peripheral immune tolerance on the other.
Naturally occurring regulatory Tcells (Treg), have been shown to play an
essential role in establishing the balance between pro- and anti-
inﬂammatory mechanisms in the periphery and maintaining self-tol-
erance both in rodents and humans. Their ability to suppress T cell
responses and thereby regulate immune reactions ascribes them a key
role in the pathophysiology of inﬂammation and makes them an
interesting target for treatment. The presence of Tregs in OA joints and
their functional status has not been assessed yet.
In this study we aimed to investigate the presence of Tregs in OA
patients and tomap their distribution between periphery and the target
organ. Datawere put in relation to resting Tcells and activated effector T
cells. Further, we assessed functional differences between peripheral
and synovial Tregs.
Methods: Data on 44 OA patients were prospectively collected. The
presence and phenotype of CD4þCD25- naive (Tn), CD4þCD25þ
CD127þ activated effector (Teff) and CD4þCD25þ/highCD127low/-
Tregs were assessed in concurrent samples of synovial membrane,
synovial ﬂuid (SF) and peripheral blood (PB) by multicolor ﬂow
cytometry analysis. Further, we analyzed functional differences
between peripheral and synovial Tregs by surface markers repre-
sentative of activation (CD45RA, CD45R0, CD69, CD62L), memory and
regulation (CD152, CD154, CD223, CD274, CD279, GITR).
Results: The synovial membrane contained a signiﬁcantly higher con-
centration of inﬁltrating CD4þ T cells in comparison to SF. A signiﬁcant
change of CD4þ T cell subsets was shown in the joint samples when
compared to PB, displaying the same pattern for SF and SM.
CD4þCD25þ/highCD127low/- Tregs showed a signiﬁcant accumulation
into the synovial ﬂuid (14.9  4 % of CD4þ T cells) and membrane (12 
5) when compared to concurrent PB samples (8.4  4.2; p < 0.05). In SF
a signiﬁcant decrease of CD4þCD25- Tns (23  15) was found when
compared to PB (40  9.2; p < 0.05) without any signiﬁcant change in
CD4þCD25þCD127þ Teffs (PB: 39.3  8.5; SF 42  11; n.s.). In SM the
decrease of CD4þCD25- Tns was even more evident (14  11.5, p <
0.001). Here, the percentage of CD4þCD25þCD127þ Teffs (OA: 51 17)
was signiﬁcantly increased compared to concurrent PB samples (OA:
39.3  8.5; p < 0.05). Both, PB and SM Tregs displayed a memory
phenotype (CD45ROþRA-) but synovial Tregs were activated effector
memory cells (CD62L-CD69þ), while peripheral Tregs were resting
central memory cells (CD62LþCD69-). Further, PB and SM Tregs sig-
niﬁcantly differed in markers associated with Treg function (CD152,
CD154, CD274, CD279, GITR).
Conclusions: This is, to the authors’ best knowledge, the ﬁrst study to
show that Tregs are enriched in OA joints. One underlying hypothesis
about Treg enrichment into the affected joints of inﬂammatory diseases
is that Tregs are either attracted or generated due to on-going inﬂam-
mation. We further detected a signiﬁcant increase of Teffs in the SM.
This taken into account, the accumulated Treg presence in the joints
could be understood as an attempt of the immune system to control the
inﬂammatory responses. Further, we showed that synovial Treg show
signiﬁcant increase of activation markers and markers associated with
Treg function suggesting that synovial Tregs are active and contribute to
joint homeostasis. Increasing Treg mediated suppressive capacity in the
joints could provide a new therapeutic approach in OA treatment.817
A SPLICE VARIANT OF ADAMTS4 IS EXPRESSED AS A PROTEIN IN
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Purpose: Osteoarthritis (OA) is a multifaceted disease involving
pathological changes in the articular cartilage, subchondral bone, sur-
rounding soft tissues, and synovium. Inﬂammation and proliferation of
synovium occurs in both early and late stage OA, and the synovium
produces many proinﬂammatory cytokines and destructive enzymes.
OA synovium is known to produce the ADAMTS4 and ADAMTS5 met-
alloproteinases, key enzymes in the cleavage of aggrecan and degra-
dation of cartilage. Aggrecan degradation is a crucial early event in the
pathogenesis of OA, and studies have found evidence for the involve-
ment of either ADAMTS4 or ADAMTS5, or both these enzymes, in the
progression of OA.
We have previously described a mRNA variant of ADAMTS4
(ADAMTS4_v1) in human synovial cell co-cultures obtained from OA
patients. This RNA message has only been found in OA synovium, and
not in OA cartilage or other tissues. If translated, it would result in a
protein identical to ADAMTS4, except that the C-terminal spacer
domain would be completely different, without homologies to
ADAMTS4. Thus it would be predicted to retain enzyme speciﬁcity for
aggrecan degradation, although properties dependent on the ADAMTS4
spacer domain would be lost. The purpose of this study was to deter-
mine if ADAMTS4_v1 is translated into a protein, expressed in vivo, and
capable of acting as an aggrecanase and cleaving other matrix
proteoglycans.
Methods: Polyclonal antibodies were raised against synthetic peptides
representing unique amino acid sequences in the C-terminus of
ADAMTS4_v1 protein. After these antibodies had been characterised, an
immunohistochemical study of human OA synovium was performed. A
mammalian expression vector coding for FLAG-tagged human
ADAMTS4 was mutated to contain the different sequence of
ADAMTS4_v1 and the resultant plasmid was used to transfect HEK293
cells. ADAMTS4_v1 protein produced by these cells was puriﬁed via the
FLAG epitope, and the ability of this recombinant protein to cleave
aggreacan, biglycan and decorin was investigated.
Results: An antibody speciﬁc for ADAMTS4_v1 protein was found to
bind to the synovial membrane surface on cryosections of human OA
synovium. The staining was most prominent in the superﬁcial layer of
the synovial membrane. The ADAMTS4_v1 protein could be detected in
cell lysates from OA synovial samples. The recombinant ADAMTS4_v1
protein demonstrated enzyme activity towards the target substrate in a
commercial aggrecanase 1 enzyme-linked immunosorbent assay. It was
also found to cleave aggrecan at the pathologically important Glu373 Y
374Ala aggrecanase site, and to cleave biglycan but not decorin.
Conclusions: The splice variant of ADAMTS4 (ADAMTS4_v1) is
expressed as a protein in vivo in human OA synovium, functions as an
aggrecanase, and cleaves other proteoglycan substrates. This splice
variant may be an important contributor to the loss of aggrecan from
the superﬁcial zone of OA cartilage.
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O. Malaise, B. Relic, E. Charlier, S. Neuville, D. de Seny, M. Malaise. GIGA
Res. – Univ. of Liege – CHU Liege, Liege, Belgium
Purpose: Osteoarthritis (OA) can be considered as a metabolic disorder
and adipokine leptin is involved in osteoarthritis pathogenesis: leptin
synovial levels are higher in patients with OA knee than in control
subjects and leptin synovial and serum levels are correlated to the
radiologic severity of OA knee. We have previously shown that synovial
ﬁbroblasts themselves were able to produce leptin in vitro, with a
strong induction under glucocorticoid prednisolone treatment. Gluco-
corticoids are powerful anti-inﬂammatory drugs and glucocorticoid-
induced leucine zipper (GILZ) mediates parts of its anti-inﬂammatory
effect. In collagen-induced arthritis and in rheumatoid arthritis synovial
ﬁbroblasts, GILZ shows an anti-inﬂammatory action. On the other hand,
